Entering text into the input field will update the search result below

Evelo Biosciences, Inc (EVLO) CEO Simba Gill on Q1 2021 Results - Earnings Call Transcript

May 01, 2021 1:18 AM ETEvelo Biosciences, Inc. (EVLO)
SA Transcripts profile picture
SA Transcripts

Evelo Biosciences, Inc (NASDAQ:EVLO) Q1 2021 Earnings Conference Call April 29, 2021 8:30 AM ET

Company Participants

Jessica Cotrone – Vice President

Simba Gill – Chief Executive Officer

Mark Bodmer – President of R&D and Chief Scientific Officer

Jonathan Zung – Chief Development Officer

Conference Call Participants

Roger Song – Jefferies

Matthew Luchini – BMO Capital

Matthew Harrison – Morgan Stanley

Joe Thome – Cowen and Company


Good morning, and welcome to Evelo Biosciences conference call to discuss the first-quarter 2021 financial results and business highlights. [Operator instructions] Please be advised that this call is being recorded at the company’s request. At this time, I’d like to turn the call over to Jessica Cotrone of Evelo. Please proceed.

Jessica Cotrone

Thank you. This morning we issued the press release that outlines the topics we plan to discuss today. This release is available at www.evelobio.com under the investors tab. Today in our call, we have Simba Gill, chief executive officer; Mark Bodmer, president of R&D and chief scientific officer; and Jonathan Zung, chief development officer.

Before we begin, I would like to remind everyone that statements made during this conference call that do not relate to matters of historical fact, including statements about our objectives and anticipated clinical milestones, the impact of our product candidates and the timing and results of our clinical studies should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual results could differ materially from those indicated by the forward-looking statements due to the impact of many factors. Participants are directed to the risk factors set forth in Evelo’s quarterly report on Form 10-Q for the three months ended March 31, 2021 and the company’s other filings

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About EVLO

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on EVLO

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.